Escherichia coli

For the expres­sion of a recom­bi­nant pro­tein in a bac­te­r­i­al sys­tem, ARTES pro­vides a high­ly effi­cient E. coli plat­form. The plat­form is char­ac­ter­ized with a host/vector tool­box for opti­mal expres­sion and with the abil­i­ty to release recom­bi­nant pro­teins into the cul­ture supernatant.

Because of the releas­ing fea­ture, the iden­ti­fi­ca­tion and purifi­ca­tion of the recom­bi­nant pro­tein after fer­men­ta­tion is much eas­i­er than in a nor­mal E. coli fer­men­ta­tion process. After fer­men­ta­tion, the pro­tein will be found in the super­natant of the broth. For the purifi­ca­tion process, steps as cell dis­rup­tion or fold­ing and refold­ing will not be nec­es­sary any more. The secre­tion prop­er­ty of our E. coli sys­tem flows direct­ly into the effi­cien­cy of pro­duc­tion costs for the man­u­fac­tur­ing of the recom­bi­nant prod­uct of our client.

Hansenula polymorpha

ARTES uses one of the most impor­tant indus­tri­al expres­sion sys­tems, the methy­lotroph­ic yeast Hansenu­la poly­mor­pha (syn. Pichia angus­ta). For our plat­form tech­nol­o­gy, we have all rel­e­vant IP rights as well as unpatent know-how. Our exper­tise is on trou­ble-shoot­ing and project man­age­ment. ARTES ensures 100% free­dom-to-oper­ate for all clients and licensees and guar­an­tees a smooth and high stan­dard project progress.

Fea­tures of Hansenu­la tech­nol­o­gy platform:

  • large tool­box (e.g. expres­sion vec­tors, secre­tion sig­nals, chaperones)
  • sta­ble co-expres­sion of mul­ti­ple genes
  • high copy pro­duc­tion cell lines with up to 120 genes per cell
  • 100% sta­bil­i­ty of pro­duc­tion cell lines for so far > 25 years
  • absence of aller­gens, tox­ins and viral contaminations
  • secret­ed prod­ucts with­out con­t­a­m­i­nat­ing host cell pro­teins (> 90% puri­ty in fer­men­ta­tion broth)
  • high yield pro­duc­tion of intra-cel­lu­lar sol­u­ble proteins
  • meta­bol­ic engi­neer­ing for design of whole-cell biocatalysts
  • organ­ism known at and rec­om­mend­ed by a.o. US-FDA, EMA, EFSA and WHO
  • antibi­ot­ic resis­tance free host vec­tor system